CorMedix, Inc.
(NASDAQ : CRMD)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. -0.37%242.401.5%$875.87m
MRNAModerna, Inc. 4.98%149.970.0%$810.80m
VRTXVertex Pharmaceuticals, Inc. 0.27%282.541.9%$481.11m
GILDGilead Sciences, Inc. -0.36%61.591.0%$473.71m
REGNRegeneron Pharmaceuticals, Inc. -0.37%588.932.6%$469.91m
NVAXNovavax, Inc. 10.75%56.9675.7%$441.37m
ILMNIllumina, Inc. 1.54%187.203.3%$341.04m
SNSSSunesis Pharmaceuticals, Inc. -2.84%3.770.7%$263.54m
BIIBBiogen, Inc. 1.26%206.511.8%$241.07m
BNTXBioNTech SE 4.41%155.680.0%$195.41m
CRSPCRISPR Therapeutics AG 3.11%62.660.6%$165.07m
BMRNBioMarin Pharmaceutical, Inc. 0.68%83.434.2%$116.97m
EXASEXACT Sciences Corp. 2.29%40.2917.7%$93.01m
IOVAIovance Biotherapeutics, Inc. 2.90%11.360.0%$90.66m
TECHBio-Techne Corp. 0.42%348.094.5%$89.99m

Company Profile

CorMedix, Inc. operates as a pharmaceutical and medical device company. The firm seeks to license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.